REG - Futura Medical PLC - PCA Dealing

Futura MedicalAnnouncement

Yesterday 16:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251114:nRSN6668Ha&default-theme=true

RNS Number : 6668H  Futura Medical PLC  14 November 2025

14 November 2025

Futura Medical plc

("Futura", "the Group" or the "Company")

PCA Dealing

 

Futura Medical plc (AIM: FUM), the consumer healthcare Group behind Eroxon®,
that specialises in the development and global commercialisation of
innovative and clinically proven sexual health products, announces that
Lombard Odier Asset Management (Europe) Limited, a fund closely associated
with Harmesh Suniara, Non-Executive Director, has sold 4,441,678 ordinary
shares of 0.2 pence each ('Ordinary Shares') in the Company on 13 November
2025 at a price of 1.5 pence per share. Following the sale, Lombard Odier
Asset Management (Europe) Limited hold 82,339,520 ordinary shares representing
26.90% of the company's issued share capital.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

  1   Details of the person discharging managerial responsibilities/person closely
      associated
 a)   Name                                                         Lombard Odier Asset Management (Europe) Limited
 2    Reason for the notification
 a)   Position/status                                              Fund closely associated with Harmesh Suniara, Non-Executive Director
 b)   Initial notification/Amendment                               Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         Futura Medical plc
 b)   LEI                                                          21380053QLT46UNV2303
 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.2 pence each
 b)   Identification Code                                          GB0033278473
 c)   Nature of the transaction                                    Sale of Ordinary Shares

 d)   Price(s) and volume(s)                                       1.5 pence and 4,441,678
 e)   Aggregated information

      - Aggregated volume                                           N/A

      - Price
 f)   Date of the transaction (s)                                  13 November 2025
 g)   Place of the transaction                                     London Stock Exchange, AIM

 

 

 

Contacts:

 Futura Medical plc                          Alex Duggan                       investor.relations@futuramedical.com

                                 (mailto:Investor.relations@futuramedical.com)
                                             Interim Chief Executive Officer

                                 +44 (0)1483 685 670
                                             Angela Hildreth

                                 www.futuramedical.com (http://www.futuramedical.com/)
                                             Finance Director and COO

 Panmure Liberum                             Emma Earl, Will Goode,            +44 (0)20 3100 2000

 Nominated Adviser                           Mark Rogers (Corporate Finance)

 and Broker

 Turner Pope Investments (TPI) Ltd - Broker  James Pope, Andrew Thacker        +44 (0) 20 3657 0050

 Alma Strategic Communications               Rebecca Sanders-Hewett            +44 (0)20 3405 0205

                                             Sam Modlin                        futura@almastrategic.com

                                             Emma Thompson

 

Notes to Editors:

 

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon(®) and products WSD4000 and
Eroxon(®) Intense. Our core strength lies in our research, development and
commercialisation of topically delivered gel formulations in sexual health
products.

 

Sexual health issues are prevalent in both men and women. ED impacts 1 in 5
men globally across all adult age brackets, with approximately half of all men
over 40 experiencing ED and 25% of all new diagnoses being in men under 40.
Around 60% of women experience at least one symptom of sexual dysfunction, and
only one in four women seek professional help, and remain chronically
underserved.

 

Eroxon(®), Futura's clinically proven lead product, has been developed for
the treatment of Erectile Dysfunction ("ED"). The highly differentiated
product, which is the only topical gel treatment for ED available over the
counter and helps men get an erection in ten minutes, addresses significant
unmet needs in the ED market. Eroxon(®) has been nominated for a number of
healthcare industry awards and has won two to-date.

 

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe.

 

WSD4000 is a topical treatment designed for the symptoms of impaired sexual
response and function in women. There is currently no regulatory approved OTC
treatment available for impaired sexual response and function in women.
WSD4000 has the potential to be an effective, breakthrough treatment for the
common symptoms associated with impaired sexual response and function, such as
lack of desire, arousal and lubrication.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEAKFLFDXSFFA



            Copyright 2019 Regulatory News Service, all rights reserved